Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | FGFR2 - KIAA1217 FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 V564I FGFR2 V564L FGFR2 E565A FGFR2 L617F FGFR2 L617V FGFR2 K659M FGFR2 Q746L |
Gene Variant Detail |
FGFR2 E565A (gain of function) FGFR2 K659M (gain of function - predicted) FGFR2 L617V (gain of function - predicted) FGFR2 N549D (gain of function - predicted) FGFR2 N549H (gain of function) FGFR2 N549K (gain of function) FGFR2 V564F (gain of function - predicted) |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
FGFR2 - KIAA1217 FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2 V564I FGFR2 V564L FGFR2 E565A FGFR2 L617F FGFR2 L617V FGFR2 K659M FGFR2 Q746L | cholangiocarcinoma | predicted - resistant | Infigratinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with cholangiocarcinoma harboring an FGFR2-KIAA1217 fusion experienced disease progression after 10.6 months of treatment with Truseltiq (infigratinib) and was found to have acquired additional FGFR2 mutations, N549K, N549D, N549H, V564F, V564I, V564L, E565A, L617V, L617F, K659M, Q746L (PMID: 34250419). | 34250419 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|